The effect of empagliflozin on chronic kidney disease

The effect of empagliflozin on hemoglobin levels in patients with chronic kidney disease.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251223068415N1

Enrollment

Registered

2025-12-24

Start date

2026-02-04

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention 1: Intervention group: Standard treatment + daily intake of empagliflozin 10 mg tablets for 3 months. Intervention 2: Control group: Standard treatment.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent to participate in the study Over 18 years old Glomerular filtration rate 20 to 45 Hemoglobin below 13 for men and below 12 for women

Exclusion criteria

Exclusion criteria: Unwillingness to continue participating in the study Acute kidney failure Anemia in a setting other than chronic kidney disease

Design outcomes

Primary

Measure	Time frame
Mean hemoglobin level. Timepoint: Before and after the intervention. Method of measurement: Automated laboratory device.;Mean hematocrit level. Timepoint: Before and after the intervention. Method of measurement: Automated laboratory device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Momeni

Shahre-kord University of Medical Sciences

ali.momeny@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026